Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.4061/2011/873548 |